EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudieOpen Access · CC BY 4.0

Propofol-supplemented cardioplegia: A multicenter blinded 3-group randomized trial (Propofol for Myocardial Protection Trial 2: ProMPT2)

Gianni D Angelini, Helena J M Smartt, Katherine Joyce, Rachael Heys, Rachel Maishman, Lucy Culliford, Samantha E de Jesus, Beth M Fitzgerald, M Saadeh Suleiman, Prakash Punjabi, Nnamdi Nwaejike, Richard Downes und 2 weitere

The Journal of Thoracic and Cardiovascular Surgery · 2026

DOI: 10.1016/j.jtcvs.2025.09.040 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Thoracic and Cardiovascular Surgery, 2026. Verfasst von Gianni D Angelini und 13 weiteren Autor:innen. Beteiligte Einrichtung: Bristol Heart Institute, University of Bristol, Bristol, United Kingdom. Hauptthemen laut MEDLINE: Propofol, Heart Arrest, Induced, Cardioplegic Solutions, Coronary Artery Bypass. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Bristol, Efficacy and Mechanism Evaluation Programme, Department of Health and Social Care.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Coronary artery bypass grafting using cardiopulmonary bypass and cardioplegic arrest is an effective treatment for coronary artery disease. Research suggests supplementing the cardioplegia solution with propofol may be cardioprotective. Our aim was to compare the safety and efficacy of supplementing the cardioplegia solution with different doses of propofol in adults undergoing first-time surgery. METHODS: A blinded, parallel group randomized controlled trial conducted in 3 hospitals in the United Kingdom compared a cardioplegia solution supplemented with high-dose propofol (concentration 12 μg/mL), low-dose propofol (concentration 6 μg/mL), and placebo (saline). Primary outcome was cardiac troponin T measurements over the first 48 hours after surgery. Participants were followed for 12 months. RESULTS: In total, 240 participants, median age 66 years, 90% male, were randomly allocated: 78 to high-dose propofol, 80 to low-dose propofol, and 82 to placebo. In total, 239 participants were included in the primary analysis. Geometric mean cardiac troponin release at 48 hours (95% confidence interval) was 145 ng/L (125-168), 162 ng/L (138-191), and 150 ng/L (125-180) in the high-dose propofol, low-dose propofol, and placebo groups, respectively (adjusted geometric mean ratio 1.06; 95% confidence interval, 0.97-1.15; P = .20, for pairwise comparisons between high- and low-dose propofol and between low-dose propofol and placebo). A total of 96 adverse events that prolonged the hospital stay or were life-threatening were reported (33, 26, and 37 in the high-dose propofol, low-dose propofol, and placebo groups, respectively), as well as 4 deaths (1 low-dose propofol group, 3 placebo group). CONCLUSIONS: Propofol supplementation of warm blood cardioplegia at both the lower and higher concentrations is safe, but there is no evidence to suggest either dose is cardioprotective.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PropofolHeart Arrest, InducedCardioplegic SolutionsCoronary Artery BypassHumansMaleFemaleAgedMiddle AgedTroponin TTreatment OutcomeTime FactorsBiomarkersUnited Kingdom

Stichwörter der Autor:innen

cardioplegiacardiopulmonary bypasscoronary artery bypass surgeryischemiapropofolrandomizedreperfusion

Substanzen

PropofolCardioplegic SolutionsTroponin TBiomarkers

Autor:innen und Institutionen

  • Bristol Heart Institute, University of Bristol, Bristol, United Kingdom.
  • Bristol Trials Centre, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
  • National Heart and Lung Institute, Imperial College London, London, United Kingdom; Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom.
  • Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, United Kingdom.
  • Perfusion Department, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom.
  • Bristol Trials Centre, Bristol Medical School, University of Bristol, Bristol, United Kingdom. Electronic address: chris.rogers@bristol.ac.uk.

Förderung

  • University of Bristol
  • Efficacy and Mechanism Evaluation Programme
  • Department of Health and Social Care
  • Medical Research Council
  • National Institute for Health and Care Research

Zitieren

APA

Angelini, G. D., Smartt, H. J. M., Joyce, K., Heys, R., Maishman, R., Culliford, L., de Jesus, S. E., Fitzgerald, B. M., Suleiman, M. S., Punjabi, P., Nwaejike, N., Downes, R., Gibbison, B., & Rogers, C. A. (2026). Propofol-supplemented cardioplegia: A multicenter blinded 3-group randomized trial (Propofol for Myocardial Protection Trial 2: ProMPT2). The Journal of Thoracic and Cardiovascular Surgery. https://doi.org/10.1016/j.jtcvs.2025.09.040

Vancouver

Angelini GD, Smartt HJM, Joyce K, Heys R, Maishman R, Culliford L, et al. Propofol-supplemented cardioplegia: A multicenter blinded 3-group randomized trial (Propofol for Myocardial Protection Trial 2: ProMPT2). The Journal of Thoracic and Cardiovascular Surgery. 2026. doi:10.1016/j.jtcvs.2025.09.040

BibTeX
@article{Angelini2026,
  author = {Angelini, Gianni D and Smartt, Helena J M and Joyce, Katherine and Heys, Rachael and Maishman, Rachel and Culliford, Lucy and de Jesus, Samantha E and Fitzgerald, Beth M and Suleiman, M Saadeh and Punjabi, Prakash and Nwaejike, Nnamdi and Downes, Richard and Gibbison, Ben and Rogers, Chris A},
  title = {Propofol-supplemented cardioplegia: A multicenter blinded 3-group randomized trial (Propofol for Myocardial Protection Trial 2: ProMPT2)},
  journal = {The Journal of Thoracic and Cardiovascular Surgery},
  year = {2026},
  doi = {10.1016/j.jtcvs.2025.09.040}
}
Kostenlos starten →